A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 145 participants.
Also called NCT01570751
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 145 participants
- Sponsor
- Registry
-
NCT01570751
-
- Other papers using this trial's data
- Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01570751. Randomized; no masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2015-11-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01570751- Content hash
77f680d3985c4db8bdfd1638aa5c26342415d931e618b956e1ea19d603db9798